Publications

Forlenza CJon, Rosenzweig J, Mauguen A, Buhtoiarov IN, Cuglievan B, Dave H, Deyell R, Flerlage JE, Franklin ARK, Krajewski J et al..  2023.  Brentuximab Vedotin Following Autologous Transplantation in Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma.. Blood Adv.

Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM.  2023.  Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma.. Pediatr Blood Cancer. :e30580.

El-Mallawany NKim, Alexander S, Fluchel M, Hayashi RJ, Lowe EJ, Giulino-Roth L, Wistinghausen B, Hermiston M, Allen CE.  2023.  Children's Oncology Group's 2023 blueprint for research: Non-Hodgkin lymphoma.. Pediatr Blood Cancer. :e30565.

Belsky JA, Hochberg J, Giulino-Roth L.  2023.  Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults.. Best Pract Res Clin Haematol. 36(1):101445.

Gulati N, Giulino-Roth L.  2023.  Do no harm: Distinguishing between rebound thymic hyperplasia and Hodgkin lymphoma relapse in children.. Pediatr Blood Cancer. :e30492.

Toor RK, Semmes EC, Walsh KM, Permar SR, Giulino-Roth L.  2023.  Does congenital cytomegalovirus infection contribute to the development of acute lymphoblastic leukemia in children? Curr Opin Virol. 60:101325.

Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KWha, Uppal M, He F et al..  2023.  Molecular evolution of classic Hodgkin lymphoma revealed through whole genome sequencing of Hodgkin and Reed Sternberg cells.. Blood Cancer Discov.

Giulino-Roth L.  2023.  Pembrolizumab in PMBCL: can it go the distance? Blood. 142(2):121-122.

Forlenza CJ, Chadburn A, Giulino-Roth L.  2023.  Primary Mediastinal B-Cell Lymphoma in Children and Young Adults.. J Natl Compr Canc Netw. 21(3):323-330.

Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, Doench JG, O'Reilly RJ, Cesarman E, Giulino-Roth L et al..  2022.  Author Correction: DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression.. Nat Microbiol. 7(6):928.

Guo R, Liang JHua, Zhang Y, Lutchenkov M, Li Z, Wang Y, Trujillo-Alonso V, Puri R, Giulino-Roth L, Gewurz BE.  2022.  Methionine metabolism controls the B cell EBV epigenome and viral latency.. Cell Metab. 34(9):1280-1297.e9.

Egg D, Rump ICaroline, Mitsuiki N, Rojas-Restrepo J, Maccari M-E, Schwab C, Gabrysch A, Warnatz K, Goldacker S, Patiño V et al..  2022.  Therapeutic options for CTLA-4 insufficiency.. J Allergy Clin Immunol. 149(2):736-746.

Llaurador G, Giulino-Roth L.  2021.  AYA Considerations for Aggressive Lymphomas.. Curr Hematol Malig Rep. 16(1):61-71.

Collins GP, Eyre TA, Schmitz-Rohmer D, Townsend W, Popat R, Giulino-Roth L, Fields PA, Krasniqi F, Soussain C, Stathis A et al..  2021.  A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma.. Hemasphere. 5(11):e656.

Giulino-Roth L, Pei Q, Buxton A, Bush R, Wu Y, Wolden SL, Constine LS, Kelly KM, Schwartz CL, Friedman DL.  2021.  Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.. Blood. 137(11):1449-1456.

Scholze H, Stephenson RE, Reynolds R, Shah S, Puri R, Butler SD, Trujillo-Alonso V, Teater MR, van Besien H, Gibbs-Curtis D et al..  2020.  Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes.. Blood Adv. 4(20):5226-5231.

Guo R, Zhang Y, Teng M, Jiang C, Schineller M, Zhao B, Doench JG, O'Reilly RJ, Cesarman E, Giulino-Roth L et al..  2020.  DNA methylation enzymes and PRC1 restrict B-cell Epstein-Barr virus oncoprotein expression.. Nat Microbiol. 5(8):1051-1063.

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, Vizconde T, Savalia B, Dyomin V, Weigel C et al..  2020.  Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy.. Blood. 135(21):1870-1881.

Guo R, Jiang C, Zhang Y, Govande A, Trudeau SJ, Chen F, Fry CJ, Puri R, Wolinsky E, Schineller M et al..  2020.  MYC Controls the Epstein-Barr Virus Lytic Switch.. Mol Cell. 78(4):653-669.e8.

Chu Y, Lee S, Shah T, Yin C, Barth M, Miles RR, Ayello J, Morris E, Harrison L, Van de Ven C et al..  2019.  Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.. Oncoimmunology. 8(1):e1512455.

Roth L, Moerdler S, Weiser D, Douglas L, Gill J, Roth M.  2019.  Otolaryngologist and pediatric oncologist perspectives on the role of fine needle aspiration in diagnosing pediatric head and neck masses.. Int J Pediatr Otorhinolaryngol. 121:34-40.

Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot J-M, Leonard JP, Ribrag V, McCabe MT, Creasy CL et al..  2019.  Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.. Clin Cancer Res. 25(24):7331-7339.

Attarbaschi A, Abla O, Ronceray L, Bansil S, Bomken S, Burkhardt B, Ceppi F, Chiang AKS, Dave H, Fedorova A et al..  2019.  Primary central nervous system lymphoma: initial features, outcome, and late effects in 75 children and adolescents.. Blood Adv. 3(24):4291-4297.

Gulati N, Béguelin W, Giulino-Roth L.  2018.  Enhancer of zeste homolog 2 (EZH2) inhibitors.. Leuk Lymphoma. 59(7):1574-1585.

Egg D, Schwab C, Gabrysch A, Arkwright PD, Cheesman E, Giulino-Roth L, Neth O, Snapper S, Okada S, Moutschen M et al..  2018.  Increased Risk for Malignancies in 131 Affected CTLA4 Mutation Carriers.. Front Immunol. 9:2012.